CPA Russo - Bionik Laboratories CEO Pres
Insider
CPA Russo is CEO Pres of Bionik Laboratories Corp
| Age | 43 |
| Phone | 617 926 4800 |
| Web | https://www.bioniklabs.com |
Bionik Laboratories Management Efficiency
The company has return on total asset (ROA) of (0.6375) % which means that it has lost $0.6375 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.8325) %, meaning that it created substantial loss on money invested by shareholders. Bionik Laboratories' management efficiency ratios could be used to measure how well Bionik Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | INSIDER Age | ||
| Kevin Pitts | Grey Cloak Tech | 63 | |
| Robert Madden | Grey Cloak Tech | 51 | |
| Scott Landers | Grey Cloak Tech | N/A | |
Management Performance
| Return On Equity | -7.83 | |||
| Return On Asset | -0.64 |
Bionik Laboratories Corp Leadership Team
Elected by the shareholders, the Bionik Laboratories' board of directors comprises two types of representatives: Bionik Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bionik. The board's role is to monitor Bionik Laboratories' management team and ensure that shareholders' interests are well served. Bionik Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bionik Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA Russo, CEO Pres | ||
| Michal Prywata, Co-Founder, COO and Director | ||
| Mark Eiseman, Sales Director | ||
| Daniel CPA, Ex CFO | ||
| Dan CPA, Ex CFO | ||
| John Smathers, Director Operations |
Bionik Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bionik Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.83 | |||
| Return On Asset | -0.64 | |||
| Operating Margin | (3.30) % | |||
| Current Valuation | 4.84 M | |||
| Shares Outstanding | 6.88 M | |||
| Shares Owned By Insiders | 61.64 % | |||
| Shares Owned By Institutions | 1.18 % | |||
| Price To Earning | (3.60) X | |||
| Price To Book | 8.04 X | |||
| Price To Sales | 3.82 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Bionik Pink Sheet
Bionik Laboratories financial ratios help investors to determine whether Bionik Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bionik with respect to the benefits of owning Bionik Laboratories security.